Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
3Customers
3Debt Items
12Related Chains
Source-Backed Evidence Depth
Galectin Therapeutics Inc. (GALT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
8High confidence
0.821Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Galectin Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
RICHARD-E-UIHLEIN
RICHARD-E-UIHLEIN
92%
The Lender shall provide the Company a line of credit of up to $10.00 million (the "Line of Credit") to finance the Company's working capital needs.
CONTRACT-RESEARCH-ORGANIZATIONS
CONTRACT-RESEARCH-ORGANIZATIONS
90%
Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors.
CROS
CROS
90%
We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial.
CONTRACT-VENDOR
CONTRACT-VENDOR
85%
The Company is involved in a dispute with a contract vendor for clinical trial management services provided outside of the United States.
Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product can…
Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our sec…
GALECTIN-SCIENCES-LLC
GALECTIN-SCIENCES-LLC
62%
. In addition to base rental payments included in the contractual obligations table above, the Company is responsible for our pro-rata share of the operating expenses for the building. Our lease cost…
SBH-SCIENCES-INC
SBH-SCIENCES-INC
62%
The Company is involved in a dispute with a contract vendor for clinical trial management services provided outside of the United States. The contract in question is a variable contract. The Company …
Galectin Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
GALT-DEBT-9711
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-04-16.
GALT-DEBT-9710
Warrants outstanding: 500000
90%
xbrl warrant detail from xbrl 2025-12-31.
GALT-DEBT
Debt stack $138.7M
90%
Market cache reports total debt of $138.7M.
Galectin Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Galectin Therapeutics Inc..
Galectin Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
GALT-OWNER-49-WEALTH-MANAGEMENT-LLC
49 WEALTH MANAGEMENT, LLC
90%
13F overlay lists 49 WEALTH MANAGEMENT, LLC as top holder; 1 tracked holders.
Galectin Therapeutics Inc. Extended Supply Chain Network
